(200 days)
The Dimension Vista® High-Sensitivity Troponin I (TNIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human plasma using the Dimension Vista system. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).
The Dimension Vista® TNIH assay is a homogeneous, sandwich chemiluminescent immunoassay based on LOCI® technology. The LOCI reagents include two synthetic bead reagents and two biotinylated anti-cardiac troponin I monoclonal antibody fragments. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with a third anticardiac troponin I monoclonal antibody and contains chemiluminescent dye. Sample is incubated with Chemibeads and biotinylated antibodies to form bead-cardiac troponin Ibiotinylated antibody sandwiches. Sensibeads are added and bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the cardiac troponin I concentration in the sample. Lithium heparin plasma specimens may be used. The reagent is stored unopened at 2 – 8 °C, is stable sealed on system for 30 days and opened on the system for 7 days. Calibration is performed every 30 days for a reagent lot.
The provided document describes the Siemens Healthcare Diagnostics Dimension Vista High-Sensitivity Troponin I (TNIH) Assay. The following information regarding its acceptance criteria and a study proving its performance is extracted:
Acceptance Criteria and Reported Device Performance
| Performance Metric | Acceptance Criteria | Reported Device Performance |
|---|---|---|
| Detection Limit | ||
| - Limit of Blank (LoB) | 95th percentile of all values, measured using a non-parametric approach. | 1.0 pg/mL |
| - Limit of Detection (LoD) | Non-parametric approach following CLSI EP17-A2. | 2.0 pg/mL (consistent with range of 0.7 - 1.9 pg/mL) |
| Limit of Quantitation (LoQ) | Analyte level with a within-lab CV of ≤ 20.0%. | 3.0 pg/mL (Lot-1: 1.2 pg/mL, Lot-2: 2.4 pg/mL, Lot-3: 2.2 pg/mL) |
| 10% CV Limit | Analyte level with a within-lab CV of ≤ 10.0%. | Consistent with 10.0 pg/mL (Lot-1: 2.7 pg/mL, Lot-2: 5.7 pg/mL, Lot-3: 5.4 pg/mL) |
| Precision | All precision goals were met. (Specific goals for SD and %CV not explicitly detailed but implied by "All precision goals were met" statement). | Repeatability: Plasma 1 (48.9 pg/mL): 1.12 SD, 2.3% CV; Plasma 2 (157.7 pg/mL): 1.55 SD, 1.0% CV; QC (8088.5 pg/mL): 99.54 SD, 1.2% CV.Within-Lab: Plasma 1: 3.05 SD, 6.2% CV; Plasma 2: 2.60 SD, 1.6% CV; QC: 200.36 SD, 2.5% CV. |
| Linearity | The p values of nonlinear terms in the quadratic and cubic fit equations are non-significant (p ≤ 0.05). If p-value > 0.05, then allowable bias is ≤ 10% or 3 pg/mL, whichever is greater. | Confirmed linearity from 3.0 - 25,000.0 pg/mL. |
| Interferences | Bias exceeding 10% is considered interference. | Exogenous Compounds: No interference detected from Hemoglobin (400 mg/dL), Bilirubin (conjugated 30 mg/dL, unconjugated 40 mg/dL), Lipemia (3000 mg/dL) at approximately 40 pg/mL and 1350 pg/mL cTnI. Numerous therapeutic/toxic substances: No interference detected at specified low/therapeutic and high/toxic concentrations (details in document for each substance). |
| High Dose Hook Effect | Not explicitly stated as a numerical criterion, but implies absence of hook effect. | No hook effect found at 1,000,000 pg/mL troponin. |
| Dilution Recovery | Supported use of diluent for over-range samples. (Specific numerical criteria not explicitly stated). | Testing supported use of the diluent for over-range samples. |
| Calibration Stability | P-value of regression slope ≥ 0.05 OR drift ≤ LoQ OR drift ≤ 10% for values up to 20,000 pg/mL OR drift ≤ 13% for values > 20,000 pg/mL. | Calibration interval measured to be 30 days. |
| Open Well Stability | P-value of regression slope ≥ 0.05 OR drift ≤ LoQ OR drift ≤ 10% for values up to 20,000 pg/mL OR drift ≤ 13% for values > 20,000 pg/mL. | Stability of reagents opened onboard the instrument was 7 days per well set. |
| Sample Stability | Lower bound of the one-sided 95% confidence interval of the regression line must be ≤ -10% AND all individual data points must have a bias of ≤ -20% when compared to time zero. | Separated samples stable for 8 hours at room temperature, 24 hours at 2-8 °C, up to 40 days at or below -20 °C (non-frost free), and up to 1 year at or below -70 °C. |
| Clinical Performance (Sensitivity) | Not explicitly stated as acceptance criteria, but clinical performance is assessed for diagnostic accuracy. | Pooled Gender (58.9 pg/mL 99th percentile): ranged from 79.0% (0-<1.5h) to 94.2% (4.5-<6h).Female (53.7 pg/mL 99th percentile): ranged from 83.3% (0-<1.5h) to 96.4% (>24h).Male (78.5 pg/mL 99th percentile): ranged from 74.0% (0-<1.5h) to 90.3% (9-24h). |
| Clinical Performance (Specificity) | Not explicitly stated as acceptance criteria. | Pooled Gender: ranged from 85.5% (>24h) to 92.5% (0-<1.5h).Female: ranged from 83.8% (>24h) to 94.4% (0-<1.5h).Male: ranged from 87.2% (9-24h) to 92.5% (0-<1.5h). |
| Clinical Performance (NPV) | Not explicitly stated as acceptance criteria. | Pooled Gender: ranged from 96.9% (0-<1.5h) to 99.0% (3.5-<4.5h and 4.5-<6h).Female: ranged from 98.2% (0-<1.5h) to 99.5% (4.5-<6h).Male: ranged from 95.4% (0-<1.5h) to 97.7% (3.5-<4.5h). |
Study Information
-
Sample size used for the test set and the data provenance:
- 99th Percentile Determination: 2021 apparently healthy individuals from the United States (1017 female, 1004 male) for lithium heparin plasma. Provenance is prospective from the United States.
- Clinical Performance Study: Approximately 2500 subjects in lithium heparin plasma. Specimens collected at 29 emergency departments across the United States. Provenance is prospective.
-
Number of experts used to establish the ground truth for the test set and the qualifications of those experts:
- 99th Percentile Determination: No explicit mention of experts establishing ground truth for healthy individuals; values were statistically determined.
- Clinical Performance Study: Panels of certified cardiologists and emergency physicians. The exact number of experts per panel is not specified, but panels are plural.
-
Adjudication method for the test set:
- For the clinical performance study, subject diagnoses were adjudicated by panels of certified cardiologists and emergency physicians according to the Third Universal Definition Of Myocardial Infarction - a consensus guideline endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF). This indicates a consensus-based adjudication process guided by established clinical criteria. The exact number of clinicians per panel or specific rules (e.g., 2+1) are not provided, but the use of "panels" implies multiple reviewers.
-
If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:
- No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. This study describes the performance of an in vitro diagnostic assay for measuring cardiac troponin I, not an AI or human-assisted diagnostic device.
-
If a standalone (i.e., algorithm only without human-in-the-loop performance) was done:
- Yes, this is a standalone study. The device is an in vitro diagnostic assay (a test kit for laboratory use) and its performance is evaluated directly. There is no AI or software algorithm being assessed for human-in-the-loop performance. Its output (troponin I concentration) is then used by clinicians for diagnosis.
-
The type of ground truth used (expert consensus, pathology, outcomes data, etc.):
- 99th Percentile Determination: Ground truth for healthy reference ranges was established by statistical analysis (non-parametric method) of values from apparently healthy individuals.
- Clinical Performance Study: Ground truth for Acute Myocardial Infarction (AMI) diagnosis was established by expert consensus based on the Third Universal Definition Of Myocardial Infarction by panels of certified cardiologists and emergency physicians. This combines clinical presentation, ECG changes, and biomarker elevation (including troponin, but adjudicated independently from the device under test).
-
The sample size for the training set:
- No training set is mentioned in the context of machine learning or AI, as this is an in vitro diagnostic assay that reports quantitative measurements. The "training" in this context refers to the development and optimization of the assay's chemical reagents and detection method.
-
How the ground truth for the training set was established:
- Not applicable, as this is not a machine learning model with a distinct training set and corresponding ground truth. The assay's performance characteristics (e.g., LoB, LoD, LoQ, linearity, precision, interference) are established through analytical studies using reference materials, spiked samples, and native clinical samples, as detailed in the "Summary of Performance Testing" section.
{0}------------------------------------------------
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food & Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
March 4, 2019
Siemens Healthcare Diagnostics, Inc. Laura Duggan Sr. Mgr. Regulatory Affairs 500 GBC Drive. M/S 514 Newark, DE 19714
Re: K182225
Trade/Device Name: Dimension Vista High-Sensitivity Troponin I (TNIH) Assay Regulation Number: 21 CFR 862.1215 Regulation Name: Creatine phosphokinase/creatine kinase or isoenzymes test system Regulatory Class: Class II Product Code: MMI Dated: January 24, 2019 Received: January 25, 2019
Dear Laura Duggan:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part
{1}------------------------------------------------
801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (OS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone
(1-800-638-2041 or 301-796-7100).
Sincerely,
Kellie B. Kelm -S
for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K182225
Device Name
Dimension Vista High-Sensitivity Troponin I (TNIH) assay
Indications for Use (Describe)
The Dimension Vista® High-Sensitivity Troponin I (TNIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human plasma using the Dimension Vista system. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).
| Type of Use (Select one or both, as applicable) |
|---|
| ------------------------------------------------- |
| X Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
SECTION 7: 510(K) SUMMARY
This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.
ASSIGNED 510(K) NUMBER
The assigned 510(k) number is K182225.
APPLICANT AND DATE
Laura J. Duggan, Ph. D., RAC Siemens Healthcare Diagnostics Inc. 500 GBC Drive, M/S 514 Newark, DE 19714-6101 Email: laura.j.duggan@siemens-healthineers.com Phone: 302-631-7654 Fax: 302-631-0493
January 24, 2018
MANUFACTURER
Siemens Healthcare Diagnostics Inc. 500 GBC Drive Newark, DE 19714-6101
Registration Number: 2517506
REGULATORY INFORMATION
Regulatory Submission for the Dimension Vista High-Sensitivity Troponin I (TNIH) Assay
| Device: | Immunoassay method, troponin subunit |
|---|---|
| Regulation Description: | Creatine phosphokinase/creatine kinase or isoenzymes test system |
| Proprietary Name: | Dimension Vista High-Sensitivity Troponin I (TNIH) Assay |
| Regulation Number: | 21CFR862.1215 |
| Classification: | Class II |
{4}------------------------------------------------
| Product Code: | MMI |
|---|---|
| Panel: | Clinical Chemistry |
| Predicate Device: | Elecsys Troponin T Gen 5 STAT(K162895) |
DEVICE DESCRIPTION
DIMENSION VISTA HIGH-SENSITIVITY TROPONIN I (TNIH) ASSAY
The Dimension Vista® TNIH assay is a homogeneous, sandwich chemiluminescent immunoassay based on LOCI® technology. The LOCI reagents include two synthetic bead reagents and two biotinylated anti-cardiac troponin I monoclonal antibody fragments. The first bead reagent (Sensibeads) is coated with streptavidin and contains photosensitizer dye. The second bead reagent (Chemibeads) is coated with a third anticardiac troponin I monoclonal antibody and contains chemiluminescent dye. Sample is incubated with Chemibeads and biotinylated antibodies to form bead-cardiac troponin Ibiotinylated antibody sandwiches. Sensibeads are added and bind to the biotin to form bead-pair immunocomplexes. Illumination of the complex at 680 nm generates singlet oxygen from Sensibeads which diffuses into the Chemibeads, triggering a chemiluminescent reaction. The resulting signal is measured at 612 nm and is a direct function of the cardiac troponin I concentration in the sample
Lithium heparin plasma specimens may be used. The reagent is stored unopened at 2 – 8 °C, is stable sealed on system for 30 days and opened on the system for 7 days. Calibration is performed every 30 days for a reagent lot.
INTENDED USE/INDICATIONS FOR USE
DIMENSION VISTA HIGH-SENSITIVITY TROPONIN I (TNIH) ASSAY
The Dimension Vista High-Sensitivity Troponin I (TNIH) assay is for in vitro diagnostic use in the quantitative measurement of cardiac troponin I in human plasma using the Dimension Vista® system. The assay can be used to aid in the diagnosis of acute myocardial infarction (AMI).
SUBSTANTIAL EQUIVALENCE COMPARISON
Below is a substantial equivalence comparison for the Dimension Vista High-Sensitivity Troponin I (TNIH) Assay vs. the Elecsys Troponin T Gen 5 STAT (K162895) device.
{5}------------------------------------------------
| Feature | Predicate Device:Elecsys Troponin T Gen 5STAT (K162895) | New Device:DIMENSION VISTA HIGH-SENSITIVITY TROPONIN I(TNIH) ASSAY |
|---|---|---|
| Intended Use : | Immunoassay for the in vitroquantitative determination ofcardiac troponin T (cTnT) inlithium heparin plasma. | The High-Sensitivity TroponinI (TNIH) assay is for in vitrodiagnostic use in thequantitative measurement ofcardiac troponin I in humanplasma using the DimensionVista® system. |
| Indications for Use: | The immunoassay isintended to aid in thediagnosis of myocardialinfarction. | The assay can be used to aidin the diagnosis of acutemyocardial infarction (AMI). |
| Device Technology: | Electrochemiluminescenceimmunoassay | Homogeneous immunoassay |
| Sample Type: | Lithium Heparin Plasma | Lithium Heparin plasma |
| Expected Values: | 99th percentilewere determined to be:• 19 ng/L for both• 14 ng/L for females• 22 ng/L for males | 99th percentile determined forplasma58.9 pg/mL overallfemale 53.7 pg/mL plasmamale 78.5 pg/mL plasma |
| CalibrationFrequency: | after 12 weeks when usingthe same reagent lot | 30 days for any one lot |
| Analytical MeasuringInterval: | 6-10,000 ng/L | 3.0 – 25,000.0 pg/mL [ng/L] |
| Interferences: | No interference in plasma at:Hemoglobin - 100 mg/dLBilirubin 25 mg/dLLipemia (Intralipid®) — 1500mg/dL | No interferences in plasma atapproximately 40 pg/mL andapproximately 1350 pg/mL ofcardiac troponin I from:Hemoglobin - 400 mg/dLBilirubin (Unconjugated) – 40mg/dL |
| Bilirubin (Conjugated) – 30md/dLLipemia (Intralipid®) - 3000mg/dL | ||
| Calibrators: | Elecsys Troponin T Gen 5STAT calibrators (CalSetTroponin T Gen 5 STAT) | High-Sensitivity Troponin ICalibrator (TNIH Cal), Cat.No. KC627 |
{6}------------------------------------------------
SUMMARY OF PERFORMANCE TESTING
Assay performance results for the Dimension Vista High-Sensitivity Troponin I (TNIH) assay was determined by processing the appropriate body fluids. Summary statistics for each are provided. The following data represent typical assay performance. All data were collected on the Dimension Vista 1500 Analyzer.
DETECTION LIMIT
The Limit of Blank (LoB) and Limit of Detection (LoD) were evaluated in accordance with CLSI EP17-A2 Protocols for Determination of Limits of Detection and Limits of Quantitation: Approved Guideline.
Assessment of LoB was the 95th percentile of all values (sorted from lowest to highest), using non-parametric approach. LoB Rank Position = 0.5 +0.95*B, where B=total reps=60; Rank = 57.5
The nonparametric approach described in EP17-A2 was followed to determine the Limit of Detection. LoD was tested separately for lithium heparin specimens.
| Dimension Vista High-Sensitivity Troponin I (TNIH) - Limit of Detection Results | ||
|---|---|---|
| Limit | Protocol | Result |
| LoB | 5 samples with no analyte (calibrator Level 1)were tested (N=4) for 3 days, one run per day, 3reagent lots | 1.0 pg/mL |
| LoD | At least 5 low analyte samples were tested (N=4)for 3 days for native lithium heparin plasma, onerun per day, 3 reagent lots | 0.7 - 1.9pg/mL |
Results are consistent with a LoB of 1.0 pg/mL and a LoD of 2.0 pg/mL
{7}------------------------------------------------
The Limit of Quantitation (LoQ) for plasma was determined as the analyte level with a within-lab CV of less than or equal to 20.0%. Testing was completed two times a day (n=2) for at least 20 days for a total of 80 replicates with at least 6 native lithium heparin plasma pools on one instrument.
LoQ Lot Summary
| Reagent Lot | Lot-1 | Lot-2 | Lot-3 |
|---|---|---|---|
| Lithium Heparin Plasma 20% CV (pg/mL) | 1.2 | 2.4 | 2.2 |
The LoQ for Dimension Vista TNIH was determined to be 3.0 pg/mL.
For lithium heparin plasma the analyte level with a within-lab CV of less than or equal to 10.0% was determined using CLSI EP5-A3, Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline - Third Edition. Testing was completed two times a day (n=2) for at least 20 days for a total of 80 replicates with at least 6 native lithium heparin plasma pools on one instrument.
10% CV Lot Summary
| Reagent Lot | Lot-1 | Lot-2 | Lot-3 |
|---|---|---|---|
| Lithium Heparin Plasma 10% CV (pg/mL) | 2.7 | 5.7 | 5.4 |
The 10% CV limit for Dimension Vista TNIH of 10.0 pg/mL is consistent with the data.
PRECISION STUDIES
Precision testing was performed in accordance with CLSI EP05-A3 Evaluation of Precision Performance of Quantitative Measurement Methods: Approved Guideline -Third Edition. Precision was tested n = 2 replicates, two times a day for at least 20 days for a total of 80 replicates with controls and plasma pools on one instrument. Analysis of variance (ANOVA) was used to evaluate the data consistent with the recommendations of EP05-A3. The data are summarized in the following table. All precision goals were met.
| Repeatability | Within-Lab | ||||
|---|---|---|---|---|---|
| Material | Mean pg/mL | SDa pg/mL | %CVb | SD pg/mL | %CV |
| Plasma 1 | 48.9 | 1.12 | 2.3 | 3.05 | 6.2 |
| Plasma 2 | 157.7 | 1.55 | 1.0 | 2.60 | 1.6 |
| QC | 8088.5 | 99.54 | 1.2 | 200.36 | 2.5 |
aSD = standard deviation
{8}------------------------------------------------
b CV = coefficient of variation
LINEARITY STUDY
Linearity was evaluated with 16 lithium heparin plasma samples which spanned the assay measuring interval. Each was prepared by mixing high and low concentration samples across the measurement interval as described in CLSI Evaluation of the Linearity of Quantitative Measurement Procedure (EP06-A). The high samples and the low samples for lithium heparin plasma were native. At least five replicates were measured for each sample. The mean of these replicates was used for the calculations.
The assay was considered linear across the measuring interval if the p values of nonlinear terms in the quadratic and cubic fit equations are nonsignificant (p ≤ 0.05). If the p-value is > 0.05, then the allowable bias is ≤ 10% or 3 pg/mL, whichever is greater.
The testing confirmed linearity from 3.0 - 25,000.0 pg/mL.
INTERFERENCES
CLSI EP7-A2 was followed for the interference testing. The interference study was conducted using a "paired difference scenario" approach where these compounds were spiked into fresh sample pools containing either low or high levels of troponin in lithium heparin troponin I pools. All exogeneous compounds were spiked into the troponin control pools at two levels. Endogeneous compounds were only tested at elevated levels as they are natively found in specimen samples.
Bias is the difference in the results between the control sample (without the interferent) and the test sample (contains the interferent) expressed in percent. Bias exceeding 10% is considered interference. Dilution studies were conducted to determine the level at which the spiked substance no longer displayed significant interference. Dilution studies were conducted at two analyte concentrations, if both sample pools show significant interference.
| Substance Tested | Substance concentration | Bias (%) |
|---|---|---|
| Hemoglobin hemolysate (monomer) | 400 mg/dL [0.25 mmol/L] | <10 |
| Bilirubin (conjugated) | 30 mg/dL [356 $\mu$ mol/L] | <10 |
| Bilirubin (unconjugated) | 40 mg/dL [684 $\mu$ mol/L] | <10 |
| Lipemia (Intralipid®) | 3000 mg/dL [33.9 mmol/L] | <10 |
No interference was detected at the following analyte concentrations.
| Low or Therapeutic Concentration | High or Toxic Concentration | |||
|---|---|---|---|---|
| Potential Interferent | Conventional Units | SI Units | Conventional Units | SI Units |
| Abciximab | 0.4 mg/dL | NA | 4.0 mg/dL | NA |
| Acetaminophen | 2.0 mg/dL | 133 µmol/L | 20.0 mg/dL | 1324 µmol/L |
| Acetylsalicylic acid | 26.1 mg/dL | 1.45 mmol/L | 65.2 mg/dL | 3.62 mmol/L |
| Allopurinol | 1.3 mg/dL | 91.9 µmol/L | 4.0 mg/dL | 294 µmol/L |
| Amiodarone | 0.2 mg/dL | 2.6 µmol/L | 0.6 mg/dL | 8.92 µmol/L |
| Ampicillin | 1.1 mg/dL | 29.1 µmol/L | 5.6 mg/dL | 152 µmol/L |
| Ascorbic acid | 1.2 mg/dL | 68.5 µmol/L | 6.0 mg/dL | 342 µmol/L |
| Atenolol | 0.1 mg/dL | 4.1 µmol/L | 1.0 mg/dL | 37.6 µmol/L |
| Biotin | 10 ng/mL | 0.04 µmol/L | 300 ng/mL | 1.2 µmol/L |
| Caffeine | 1.3 mg/dL | 64.4 µmol/L | 6.0 mg/dL | 308 µmol/L |
| Captopril | 0.1 mg/dL | 4.6 µmol/L | 0.5 mg/dL | 23 µmol/L |
| Cefoxitin | 12.63 mg/dL | 281 µmol/L | 69.5 mg/dL | 1546 µmol/L |
| Cholesterol | NA** | NA | 300 mg/dL | 7.8 mmol/L |
| Cinnarizine | 0.0285 mg/dL | 0.8 µmol/L | 2.5 mg/dL | 67.8 µmol/L |
| Clopidogrel | 0.32 mg/dL | 9.9 µmol/L | 7.5 mg/dL | 233 µmol/L |
| Cocaine | 0.05 mg/dL | 1.6 µmol/L | 1.0 mg/dL | 33 µmol/L |
| Dextran 40 | 15 g/L | 375 µmol/L | 45 g/L | 1125 µmol/L |
| Digitoxin | 17 ng/mL | 22.2 nmol/L | 60 ng/mL | 78.4 nmol/L |
| Digoxin | 1.4 ng/mL | 1.8 nmol/L | 6.1 ng/mL | 7.8 nmol/L |
| Diltiazem | 0.025 mg/dL | 0.55 µmol/L | 0.68 mg/dL | 15 µmol/L |
| Disopyramide | 0.45 mg/dL | 10.4 µmol/L | 1.3 mg/dL | 29.5 µmol/L |
| Dopamine | 0.04 mg/dL | 1.96 µmol/L | 0.11 mg/dL | 5.87 µmol/L |
| Doxycycline | 1.1 mg/dL | 22.5 µmol/L | 3.2 mg/dL | 67.5 µmol/L |
| Erythromycin | 1.1 mg/dL | 15 µmol/L | 6.0 mg/dL | 81.6 µmol/L |
| Furosemide | 2.0 mg/dL | 60.4 µmol/L | 6.0 mg/dL | 181 µmol/L |
| Ibuprofen | 4.0 mg/dL | 194.3 µmol/L | 50 mg/dL | 2425 µmol/L |
| Isosorbide dinitrate | 50.1 ng/mL | 212 nmol/L | 150.2 ng/mL | 636 nmol/L |
| Lisinopril | 0.01 mg/dL | 0.25 µmol/L | 0.33 mg/dL | 0.74 µmol/L |
| Low MW Heparin | 0.85 U/mL | NA | 2.0 U/mL | NA |
| Lovastatin | 17.2 ng/mL | 42.4 nmol/L | 80 ng/mL | 197.8 nmol/L |
| Methotrexate | 50 mg/dL | 1.1 mmol/L | 91 mg/dL | 2 mmol/L |
| Methyldopa | 0.48 mg/dL | 20.1 µmol/L | 1.69 mg/dL | 70.9 µmol/L |
| Methylprednisolone | 1.65 mg/dL | 44 µmol/L | 4.0 mg/dL | 106.8 µmol/L |
| Mexiletine | 0.15 mg/dL | 7 µmol/L | 0.48 mg/dL | 22.3 µmol/L |
| Nicotine | 0.004 mg/dL | 0.2 µmol/L | 0.10 mg/dL | 6.2 µmol/L |
| Nifedipine | 0.013 mg/dL | 361.3 nmol/L | 0.04 mg/dL | 1156.1 nmol/L |
| Nitrofurantoin | 0.20 mg/dL | 8.4 µmol/L | 0.40 mg/dL | 16.8 µmol/L |
| Nitroglycerine | 7.5 ng/mL | 33 nmol/L | 16 ng/mL | 704.5 nmol/L |
| Phenobarbital | 2.5 mg/dL | 107.8 µmol/L | 10.0 mg/dL | 431.5 µmol/L |
| Phenytoin | 1.36 mg/dL | 49.6 µmol/L | 5.43 mg/dL | 198 µmol/L |
| Primidone | 1.1 mg/dL | 48.2 µmol/L | 4.0 mg/dL | 183.5 µmol/L |
| Propranolol | 0.06 mg/dL | 1.93 µmol/L | 0.23 mg/dL | 7.71 µmol/L |
| Protein, Albumin | NA** | NA | 6 g/dL | 60 g/L |
| Protein, Gamma Globulin | 2.5 g/dL | NA | NA | NA |
| Protein, Total | NA** | NA | 12 g/dL | NA |
| Quinidine | 0.38 mg/dL | 11.7 µmol/L | 1.2 mg/dL | 37 µmol/L |
| Simvastatin | 0.004 ug/mL | 0.01 µmol/L | 32 ug/mL | 76.5 µmol/L |
| Theophylline | 1.25 mg/dL | 69.4 µmol/L | 4.0 mg/dL | 222.2 µmol/L |
| Tissue plasminogen activator(TPA) | 0.52 µg/mL | NA | 2.3 µg/mL | NA |
| Thyroxine | 0.23 mg/dL | 0.3 µmol/L | 0.6 mg/dL | 0.8 µmol/L |
| Triglyceride | 500 mg/dL | NA | 1000 mg/dL | NA |
| Trimethoprim | 1.25 mg/dL | 43.1 µmol/L | 4.0 mg/dL | 138.3 µmol/L |
| Verapamil | 0.035 mg/dL | 0.8 µmol/L | 0.22 mg/dL | 4.4 µmol/L |
| Warfarin | 0.20 mg/dL | 6.6 µmol/L | 1.0 mg/dL | 32.5 µmol/L |
{9}------------------------------------------------
{10}------------------------------------------------
**Testing at low concentrations was not appropriate for these endogenous substances.
ANALYTICAL SPECIFICITY
Cross-reactivity was determined following the governing standard CLSI document EP07-A2: Interference Testing in Clinical Chemistry; Approved Guideline-Second Edition.Cross-reactivity was tested at cTnl concentration of range of 20-60 pg/mL in native lithium heparin pools as well as in the absence of cTnl. The cross-reactants were tested at a single concentration near the upper limit of its physiological concentration. TNIH assay results from the spiked samples were compared with those of unspiked control samples. Percent cross-reactivity is calculated as:
% Cross-reactivity = [measured analyte] - [control analyte] x 100 [cross-reactant]
| Cross-reactant | Amount ng/mL [µg/L] | Cross-reactivity ( %) |
|---|---|---|
| Cardiac Troponin T | 1000 | 0.003 |
| Skeletal Troponin I | 1000 | 0.001 |
| Tropomyosin | 1000 | ND |
| Actin | 1000 | ND |
| Troponin C | 1000 | ND |
| Myosin Light Chain | 1000 | ND |
| Myoglobin | 1000 | ND |
| CK-MB | 1000 | ND |
*ND= Not detectable
HIGH DOSE HOOK EFFECT
The high dose hook effect of the TNIH assay was assessed. Normal human lithium heparin plasma were spiked with calibrator antigen. A dilution series was created and tested. No hook effect was found at 1,000,000 pg/mL troponin on the Dimension Vista TNIH assay.
{11}------------------------------------------------
DILUTION RECOVERY
Dilution recovery was evaluated for plasma at 1:2 and 1:5 dilutions using CTNI SDIL as diluent. Native human plasma samples were pooled to obtain at least three unique patient samples with TNIH levels ≥75% of the measuring interval and at least two samples above the measuring interval. For samples above the assay measuring interval the expected or neat value was determined using a 1:2 dilution in normal human plasma. Testing supported use of the diluent for over-range samples.
CALIBRATION STABILITY
The calibration stability for the TNIH assay on the Dimension Vista was determined by reading the recovery of the calibrators, commercial QC, a low patient pool and a high pool over time. The p-value of the regression slope was determined. Passing results were a p-value greater than or equal to 0.05 or drift less than or equal to the LoQ or less than or equal to10% for values up to 20,000 pg/mL and less than or equal to 13% for values greater than 20,000 pg/mL. Calibration interval was measured to be 30 days.
OPEN WELL STABILITY
The open well stability for the TNIH assay on the Dimension Vista was determined by reading the recovery of the calibrators and a low patient pool. On the first day of the study reagent packs were opened on the system and analyte was measured over the desired time interval. The p-value of the regression slope was determined. Passing results were a p-value greater than or equal to 0.05 or drift less than or equal to the LoQ or less than or equal to10% for values up to 20,000 pg/mL and less than or equal to 13% for values greater than 20,000 pg/mL. The stability of the reagents opened onboard the instrument was 7 days per well set.
SAMPLE STABILITY
Separated samples are stable for 8 hours at room temperature and for 24 hours when stored at 2-8 °C. Samples can be frozen at or below -20 °C for up to 40 days in a nonfrost free freezer and at or below -70 ℃ for up to 1 year. A linear regression analysis of the observed Troponin % Bias value (Y-axis) versus time (X-axis) was completed for each matrix. The acceptance criteria were the lower bound of the one-sided 95% confidence interval of the regression line is ≤-10% and all individual data points had a bias of ≤ -20% when compared to time zero.
{12}------------------------------------------------
Llithium heparin plasma specimens were collected from apparently healthy individuals from the United States who ranged in age from 22-91 years of age. Each specimen was frozen, thawed and assayed once. The 99th percentile values were determined using the non-parametric statistical method described in
CLSI Guidance EP28-A3c. Sample type, gender, and age had no statistically significant effect on the 99th percentile.
The combined gender and the more commonly used sample type of lithium heparin plasma were used to determine the overall observed 99th percentile of 58.9 pg/mL [ng/L]. Two female subjects had troponin values of approximately 400 pg/mL and 4700 pg/mL, and were considered to be outliers. These results were not included in the 99th percentile-determination.
The 99th percentile values determined for lithium heparin plasma (female, male, and combined), are shown in the following table. The 90% confidence intervals demonstrate that there is no statistical basis for using separate 99th percentile values based on gender or sample type.
| Sample Type | Gender | n | 99th Percentilepg/mL [ng/L] | 90% CIbpg/mL [ng/L] |
|---|---|---|---|---|
| Lithium Heparin Plasma | Female | 1017 | 53.7 | 37.7 - 115.7 |
| Lithium Heparin Plasma | Male | 1004 | 78.5 | 41.4 - 114.5 |
| Lithium Heparin Plasma | Combined | 2021 | 58.9 | 42.2 - 82.3 |
b confidence interval
CLINICAL PERFORMANCE
A prospective study was performed to assess diagnostic accuracy for approximately 2500 subjects in lithium heparin plasma sample types to evaluate clinical performance. Specimens were collected at 29 emergency departments across the United States, from subjects presenting with symptoms consistent with acute coronary syndrome (ACS).
All subject diagnoses were adjudicated by panels of certified cardiologists and emergency physicians according to the Third Universal Definition Of Myocardial Infarction - consensus guideline endorsed by the European Society of Cardiology (ESC), the American College of Cardiology Foundation (ACCF), the American Heart Association (AHA), and the World Heart Federation (WHF). The observed AMI prevalence in this study was 13.0 %.
The clinical concordance study evaluated clinical sensitivity, clinical specificity, positive predictive value (PPV) and negative predictive value (NPV) of the Dimension Vista TNIH assay in terms of its correlation to the the diagnosis of AMI. The results were analyzed using the serial sampling time points collected during the emergency department visit. A positive is defined as a sample exceeding the 99th percentile cutoff at the particular time point. The results are presented using serial timed intervals
{13}------------------------------------------------
analyzed according to the time of presentation to the emergency department. The pooled gender results based on time of presentation to the emergency department, calculated using the overall 99th percentile of 58.9 pg/mL, are summarized in Table 1.
| Sensitivity | Specificity | Positive PredictiveValue | Negative PredictiveValue | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time sincepresentation(hours) | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl |
| 0 - <1.5 | 138 | 79.0% | 71.4- 85.0 | 969 | 92.5% | 90.6- 94.0 | 182 | 59.9% | 52.6- 66.7 | 925 | 96.9% | 95.5- 97.8 |
| ≥ 1.5 - < 2.5 | 238 | 89.9% | 85.4- 93.1 | 1646 | 91.2% | 89.7- 92.5 | 359 | 59.6% | 54.5- 64.6 | 1525 | 98.4% | 97.7- 98.9 |
| ≥ 2.5 - < 3.5 | 199 | 90.5% | 85.6- 93.8 | 1377 | 90.6% | 89.0- 92.1 | 309 | 58.3% | 52.7- 63.6 | 1267 | 98.5% | 97.7- 99.0 |
| ≥ 3.5 - < 4.5 | 146 | 93.2% | 87.9- 96.2 | 1097 | 90.9% | 89.0- 92.4 | 236 | 57.6% | 51.2- 63.8 | 1007 | 99.0% | 98.2- 99.5 |
| ≥ 4.5 - < 6 | 69 | 94.2% | 86.0- 97.7 | 467 | 88.9% | 85.7- 91.4 | 117 | 55.6% | 46.5- 64.2 | 419 | 99.0% | 97.6- 99.6 |
| ≥6 - < 9 | 191 | 92.7% | 88.1- 95.6 | 913 | 87.4% | 85.1- 89.4 | 292 | 60.6% | 54.9- 66.0 | 812 | 98.3% | 97.1- 99.0 |
| ≥ 9 - 24 | 216 | 93.1% | 88.9- 95.7 | 837 | 85.5% | 83.0- 87.8 | 322 | 62.4% | 57.0- 67.5 | 731 | 97.9% | 96.6- 98.8 |
| ≥ 24 | 64 | 93.8% | 85.0- 97.5 | 254 | 85.8% | 81.0- 89.6 | 96 | 62.5% | 52.5- 71.5 | 222 | 98.2% | 95.5- 99.3 |
Table1: Pooled gender results based on time from presentation to the emergency department
Results for females based on time of presentation to the emergency department, calculated using the female-specific 99th percentile of 53.7 pg/mL for plasma are summarized in Table 2.
| Sensitivity | Specificity | Positive PredictiveValue | Negative PredictiveValue | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time sincepresentation(hours) | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl | |
| 0 - <1.5 | 42 | 83.3% | 69.4- 91.7 | 409 | 94.4% | 91.7- 96.2 | 58 | 60.3% | 47.5- 71.9 | 393 | 98.2% | 96.4- 99.1 | |
| ≥ 1.5 - < 2.5 | 77 | 89.6% | 80.8- 94.6 | 727 | 92.3% | 90.1- 94.0 | 125 | 55.2% | 46.5- 63.6 | 679 | 98.8% | 97.7- 99.4 | |
| ≥ 2.5 - < 3.5 | 71 | 94.4% | 86.4- 97.8 | 624 | 92.6% | 90.3- 94.4 | 113 | 59.3% | 50.1- 67.9 | 582 | 99.3% | 98.2- 99.7 | |
| ≥ 3.5 - < 4.5 | 50 | 94.0% | 83.8- 97.9 | 489 | 91.4% | 88.6- 93.6 | 89 | 52.8% | 42.5- 62.8 | 450 | 99.3% | 98.1- 99.8 | |
| ≥ 4.5 - < 6 | 27 | 96.3% | 81.7- 99.3 | 243 | 86.0% | 81.1- 89.8 | 60 | 43.3% | 31.6- 55.9 | 210 | 99.5% | 97.4- 99.9 | |
| ≥6-<9 | 67 | 94.0% | 85.6- 97.7 | 379 | 88.1% | 84.5- 91.0 | 108 | 58.3% | 48.9- 67.2 | 338 | 98.8% | 97.0- 99.5 | |
| ≥ 9 - 24 | 72 | 93.1% | 84.8- 97.0 | 345 | 89.0% | 85.2- 91.9 | 105 | 63.8% | 54.3- 72.4 | 312 | 98.4% | 96.3- 99.3 | |
| > 24 | 28 | 96.4% | 82.3- 99.4 | 111 | 83.8% | 75.8- 89.5 | 45 | 60.0% | 45.5- 73.0 | 94 | 98.9% | 94.2- 99.8 |
Table 2: Results for females based on time from presentation to the emergency department
Results for males based on time of presentation to the emergency department, calculated using the male-specific 99th percentile of 78.5 pg/mL for plasma are summarized in Table 3.
{14}------------------------------------------------
| Sensitivity | Specificity | Positive PredictiveValue | Negative PredictiveValue | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Time sincepresentation(hours) | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl | n | % | 95% Cl |
| 0 - <1.5 | 96 | 74.0% | 64.4- 81.7 | 560 | 92.5% | 90.0- 94.4 | 113 | 62.8% | 53.6- 71.2 | 543 | 95.4% | 93.3- 96.9 |
| ≥ 1.5 - < 2.5 | 161 | 84.5% | 78.1- 89.3 | 919 | 91.8% | 89.9- 93.4 | 211 | 64.5% | 57.8- 70.6 | 869 | 97.1% | 95.8- 98.0 |
| ≥ 2.5 - < 3.5 | 128 | 85.2% | 78.0- 90.3 | 753 | 90.4% | 88.1- 92.3 | 181 | 60.2% | 52.9- 67.1 | 700 | 97.3% | 95.8- 98.3 |
| ≥ 3.5 - < 4.5 | 96 | 86.5% | 78.2- 91.9 | 608 | 92.4% | 90.1- 94.3 | 129 | 64.3% | 55.8- 72.1 | 575 | 97.7% | 96.2- 98.7 |
| ≥ 4.5 - < 6 | 42 | 88.1% | 75.0- 94.8 | 224 | 92.0% | 87.7- 94.9 | 55 | 67.3% | 54.1- 78.2 | 211 | 97.6% | 94.6- 99.0 |
| ≥6 - < 9 | 124 | 87.9% | 81.0- 92.5 | 534 | 90.6% | 87.9- 92.8 | 159 | 68.6% | 61.0- 75.3 | 499 | 97.0% | 95.1- 98.2 |
| ≥ 9 - 24 | 144 | 90.3% | 84.3- 94.1 | 492 | 87.2% | 84.0- 89.9 | 193 | 67.4% | 60.5- 73.6 | 443 | 96.8% | 94.8- 98.1 |
| ≥ 24 | 36 | 88.9% | 74.7- 95.6 | 143 | 91.6% | 85.9- 95.1 | 44 | 72.7% | 58.2- 83.7 | 135 | 97.0% | 92.6- 98.8 |
Table 3: Results for males based on time from presentation to the emergency department
CONCLUSION
The Dimension Vista High-Sensitivity Troponin I (TNIH) Assay is substantially equivalent to the Elecsys Troponin T Gen 5 STAT (K162895) in principle and performance based on the similarity of device designs and function demonstrated through performance attributes presented.
§ 862.1215 Creatine phosphokinase/creatine kinase or isoenzymes test system.
(a)
Identification. A creatine phosphokinase/creatine kinase or isoenzymes test system is a device intended to measure the activity of the enzyme creatine phosphokinase or its isoenzymes (a group of enzymes with similar biological activity) in plasma and serum. Measurements of creatine phosphokinase and its isoenzymes are used in the diagnosis and treatment of myocardial infarction and muscle diseases such as progressive, Duchenne-type muscular dystrophy.(b)
Classification. Class II.